Under the microscopeWhen priorities shift…
We’ve intensified our focus on specific disease areas. That means some products in our diversified portfolio of medicines and vaccines have moved outside our strategic focus.
Gaborne Gajdos examines ampules at the Ampule production at the Sanofi plant in Csanyikvolgy, HungaryOpportunities arise
We out-license some of our products to help partners access novel solutions, speed up time-to-market, and explore new business directions.
Partnering success stories
Corteria
Our exclusive, worldwide license agreement with Corteria, a company backed by Kurma Partners, centers on two cardiovascular assets designed to treat some types of heart failure: a CRF2 agonist peptide and an anti-vasopressin mAb. It allows Corteria to advance our prior cardiovascular research into the clinic as a potential interceptive therapy for heart failure.
Rancho Santa Fe Bio
When we contributed Ataciguat, an oral Guanylate cyclase stimulant, to the NCAS repurposing initiative, the Mayo Clinic advanced it to clinical trials. Today, Rancho Santa Fe Bio has an exclusive, worldwide license agreement to reposition Ataciguat for calcific aortic valve stenosis. That’s how out-licensing can make science work for patients.
Your partnering lead in Out-Licensing
For more information, contact us at OutLicensingBD@sanofi.com
Matthieu Lebrun
Global Head of Business Development, Out-Licensing